Leukocyte recruitment in allergic pulmonary inflammation

Therapeutic Targets in Airway Inflammation

Volumn , Issue , 2003, Pages 223-248

  Bochner, Bruce S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0346857680     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (205)

1. Busse WW, Lemanske RF, Jr. Asthma. N Engl J Med 2001; 344:350-362.
2. Kepley CL, McFeeley PJ, Oliver JM, Lipscomb MF. Immunohistochemical detectionof human basophils in postmortem cases of fatal asthma. Am J Respir Crit Care Med2001; 164:1053-1058.
3. Bochner BS, Undem BJ, Lichtenstein LM. Immunological aspects of allergic asthma.Annu Rev Immunol 1994; 12:295-335.
4. Liu MC, Hubbard WC, Proud D, Stealey B, Galli S, Kagey-Sobotka A, BleeckerER, Lichtenstein LM. Immediate and late inflammatory responses to ragweed antigenchallenge of the peripheral airways in asthmatics: Cellular, mediator, and permeabilitychanges. Am Rev Respir Dis 1991; 144:51-58.
5. Guo CB, Liu MC, Galli SJ, Bochner BS, Kagey-Sobotka A, Lichtenstein LM. Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils.Am J Respir Cell Mol Biol 1994; 10:384-390.
6. Bochner BS. Road signs guiding leukocytes along the inflammation superhighway. JAllergy Clin Immunol 2000; 106:817-828.
7. von Andrian UH, Mackay CR. T-cell function and migration. N Engl J Med 2000;343:1020-1034.
8. D’Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F. Chemokines and theirreceptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir CritCare Med 2001; 164:1266-1275.
9. Doerschuk C. Leukocyte trafficking in alveoli and airway passages. Respir Res 2000;1:136-140.
10. Broide D, Sriramarao P. Eosinophil trafficking to sites of allergic inflammation. Immunol Rev 2001; 179:163-172.
11. Lloyd CM, Gonzalo JA, Coyle AJ, Gutierrez-Ramos JC. Mouse models of allergicairway disease. Adv Immunol 2001; 77:263-295.
12. Davenpeck K, Bochner BS. Leukocyte-blood vessel interactions. In: Zweiman B, Schwartz LB, eds. Inflammatory Mechanisms in Allergic Disease. New York: Marceldekker, Inc., 2002:125-141.
13. Bochner BS. Cellular adhesion in inflammation. In: Middleton E, C. Reed, E. Ellis, Adkinson NF, Yunginger J, Busse W, eds. Allergy Principles and Practice. 5th ed. St.Louis: Mosby, 1998:94-107.
14. Sriramarao P, von Andrian UH, Butcher EC, Bourdon MA, Broide DH. L-selectin andvery late antigen-4 integrin promote eosinophil rolling at physiological shear rates invivo. J Immunol 1994; 153:4238-4246.
15. Kikuchi M, Tachimoto M, Hudson SA, Bochner BS, Phorbol myristate acetate (PMA)alters human eosinophil expression of α4β1 and adβ2 integrins and adhesion toVCAM-1 under static and flow conditions (abstr). J Allergy Clin Immunol 2000; 105:S258.
16. Dustin ML. Adhesion molecules. In: Austen KF, Frank MM, Atkinson JP, Cantor H, eds. Samter’s Immunological Diseases. 10th ed. Philadelphia: Lippincott Williams &Wilkins, 2001:155-166.
17. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte traffickingand regional immunity. Adv Immunol 1999; 72:209-253.
18. Kitayama J, Mackay CR, Ponath PD, Springer TA. The C-C chemokine receptor CCR3participates in stimulation of eosinophil arrest on inflammatory endothelium in shearflow J Clin Invest 1998; 101:2017-2024.
19. Tachimoto H, Burdick M, Hudson SA, Kikuchi M, Konstantopoulous K, Bochner BS.CCR3-active chemokines promote rapid detachment of eosinophils from VCAM-1 invitro. J Immunol 2000; 165:2748-2754.
20. Sanchez-Madrid F, del Pozo M. Leukocyte polarization in cell migration and immuneinteractions. EMBO J 1999; 18:501-511.
21. Kay AB, Allergy and allergic diseases. Part 2. N Engl J Med 2001; 344:109-113.
22. Kay AB, Allergy and allergic diseases. Part 2. N Engl J Med 2001; 344:30-37.
23. Bochner BS, Schleimer RP. Mast cells, basophils, and eosinophils: Distinct but overlapping pathways for recruitment. Immunol Reviews 2001; 179:5-15.
24. Abraham WM, Sielczak MW, Ahmed A, Cortes A, Lauredo IT, Kim J, Pepinsky B, Benjamin CD, Leone DR, Lobb RR, Weller PF. α4-Integrins mediate antigen-inducedlate bronchial responses and prolonged airway hyperresponsiveness in sheep. J ClinInvest 1994; 93:776-787.
25. Abraham WM, Gill A, Ahmed A, Sielczak MW, Lauredo IT, Botinnikova Y, Lin KC, Pepinsky B, Leone DR, Lobb RR, Adams SP. A small-molecule, tight-binding inhibitorof the integrin α4β1 blocks antigen-induced airway responses and inflammation inexperimental asthma in sheep. Am J Respir Crit Care Med 2000; 162:603-611.
26. Das AM, Williams TJ, Lobb R, Nourshargh S. Lung eosinophilia is dependent on IL-5 and the adhesion molecules CD18 and VLA-4, in a guinea-pig model. Immunology1995; 84:41-46.
27. Chin J, Hatfield C, Winterrowd G, Brashler J, Vonderfecht S, Fidler S, Griffin R, Kolbasa K, Krzesicki R, Sly L, Staite N, Richards I. Airway recruitment of leukocytesin mice is dependent on a4-integrins and vascular cell adhesion molecule-1. Am JPhysiol 1997; 272:L219-29.
28. Bochner BS. Targeting VLA-4 integrin function: Potential therapeutic implications.In: Mousa SA, ed. Cell Adhesion Molecules Matrix Proteins in Health and Disease.Georgetown, TX: Springer-Verlag and Landes Bioscience, 1998:113-131.
29. Rabb HA, Olivenstein R, Issekutz TB, Renzi PM, Martin JG. The role of the leukocyteadhesion molecules VLA-4, LFA-1, and Mac-1 in allergic airway responses in the rat.Am J Respir Crit Care Med 1994; 149:1186-1191.
30. Pretolani M, Ruffie C, Silva JRLE, Joseph D, Lobb RR, Vargaftig BB. Antibody tovery late activation antigen 4 prevents antigen-induced bronchial hyperreactivity andcellular infiltration in the guinea pig airways. J Exp Med 1994; 180:795-805.
31. Fryer AD, Costello RW, Yost BL, Lobb RR, Tedder TF, Steeber DA, Bochner BS.Antibody to VLA-4, but not to L-selectin, protects neuronal M2 muscarinic receptorsin antigen-challenged guinea pig airways. J Clin Invest 1997; 99:2036-2044.
32. Gonzalo JA, Lloyd CM, Kremer L, Finger E, Martinez C, Siegelman MH, Cybulsky M, Gutierrez-Ramos JC. Eosinophil recruitment to the lung in a murine model ofallergic inflammation—the role of T cells, chemokines, and adhesion receptors. J ClinInvest 1996; 98:2332-2345.
33. Henderson WR, Chi EY, Albert RK, Chu SJ, Lamm WJE, Rochon Y, Jonas M, ChristiePE, Harlan JM. Blockade of CD49d (α4 integrin) on intrapulmonary but not circulatingleukocytes inhibits airway inflammation and hyperresponsiveness in a mouse modelof asthma. J Clin Invest 1997; 100:3083-3092.
34. Kanehiro A, Takeda K, Joetham A, Tomkinson A, Ikemura T, Irvin CG, Gelfand EW.Timing of administration of anti-VLA-4 differentiates airway hyperresponsiveness inthe central and peripheral airways in mice. Am J Respir Crit Care Med 2000; 162:1132-1139.
35. Gundel RH, Wegner CD, Torcellini CA, Letts LG. The role of intercellular adhesionmolecule-1 in chronic airway inflammation. Clin Exp Allergy 1992; 22:569-575.
36. Keramidaris E, Merson TD, Steeber DA, Tedder TF, Tang ML. L-selectin and intercellular adhesion molecule 1 mediate lymphocyte migration to the inflamed airway/lungduring an allergic inflammatory response in an animal model of asthma. J AllergyClin Immunol 2001; 107:734-738.
37. Broide DH, Sullivan S, Gifford T, Sriramarao P. Inhibition of pulmonary eosinophilia inP-selectin- and ICAM-1-deficientmice. Am J Respir Cell Mol Biol 1998; 18:218-225.
38. Wolyniec WW, De Sanctis GT, Nabozny G, Torcellini C, Haynes N, Joetham A, Gelfand EW, Drazen JM, Noonan TC. Reduction of antigen-induced airway hyperreactivity and eosinophilia in ICAM-1-deficient mice. Am J Respir Cell Mol Biol 1998;18:777-785.
39. Gerwin N, Gonzalo JA, Lloyd C, Coyle AJ, Reiss Y, Banu N, Wang BP, Xu H, Avraham H, Engelhardt B, Springer TA, Gutierrez-Ramos JC. Prolonged eosinophilaccumulation in allergic lung interstitium of ICAM-2-deficient mice results in extendedhyperresponsiveness. Immunity 1999; 10:9-19.
40. Gundel RH, Wegner CD, Torcellini CA, Clarke CC, Haynes N, Rothlein R, SmithCW, Letts LG. Endothelial leukocyte adhesion molecule-1 mediates antigen-inducedacute airway inflammation and late-phase airway obstruction in monkeys. J Clin Invest1991; 88:1407-1411.
41. De Sanctis GT, Wolyniec WW, Green FH, Qin S, Jiao A, Finn PW, Noonan T, JoethamAA, Gelfand E, Doerschuk CM, Drazen JM. Reduction of allergic airway responsesin P-selectin-deficient mice. J Appl Physiol 1997; 83:681-687.
42. Miller M, Sung KL, Muller WA, Cho JY, Roman M, Castaneda D, Nayar J, CondonT, Kim J, Sriramarao P, Broide DH. Eosinophil tissue recruitment to sites of allergic inflammation in the lung is platelet endothelial cell adhesion molecule independent. J Immunol 2001; 167:2292-2297.
43. Broide DH, Miller M, Castaneda D, Nayar J, Cho JY, Roman M, Ellies LG, SriramaraoP. Core 2 oligosaccharides mediate eosinophil and neutrophil peritoneal but not lungrecruitment. Am J Physiol Lung Cell Mol Physiol 2002; 282:L259-L266.
44. Fiscus LC, Van Herpen J, Steeber DA, Tedder TF, Tang ML. L-selectin is requiredfor the development of airway hyperresponsiveness but not airway inflammation in amurine model of asthma. J Allergy Clin Immunol 2001; 107:1019-1024.
45. Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K, NewmanW, Luscinskas FW, Gimbrone MA, Jr, McIntyre BW, Bochner BS. Interleukin-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: Association with expression of VCAM-1. J Immunol 1992; 148:1086-1092.
46. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. Interleukin-13selectively induces vascular cell adhesion molecule-1 (VCAM-1) expression in humanendothelial cells. J Immunol 1995; 154:799-803.
47. Thornhill MH, Haskard DO. IL-4 regulates endothelial cell activation by IL-1, tumornecrosis factor, or IFN-y. J Immunol 1990; 145:865-872.
48. Sanz MJ, Weg VB, Bolanowski MA, Nourshargh S. IL-1 is a potent inducer of eosinophil accumulation in rat skin—inhibition of response by a platelet-activating factorantagonist and an anti-human IL-8 antibody. J Immunol 1995; 154:1364-1373.
49. Moser R, Groscurth P, Carballido JM, Bruijnzeel PLB, Blaser K, Heusser CH, FehrJ. Interleukin-4 induces tissue eosinophilia in mice: Correlation with its in vitro capacityto stimulate the endothelial cell-dependent selective transmigration of human eosinophils. J Lab Clin Med 1993; 122:567-575.
50. Lukacs NW, Strieter RM, Chensue SW, Kunkel SL. Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. Am J Respir Cell Mol Biol1994; 10:526-532.
51. Rankin JA, Picarella DE, Geba GP, Temann UA, Prasad B, Dicosmo B, Tarallo A, Stripp B, Whitsett J, Flavell RA. Phenotypic and physiologic characterization oftransgenic mice expressing interleukin 4 in the lung: Lymphocytic and eosinophilicinflammation without airway hyperreactivity. Proc Natl Acad Sci USA 1996; 93:7821-7825.
52. Wills-Karp M, Luyimbazi J, Xu XY, Schofield B, Neben TY, Karp CL, DonaldsonDD. Interleukin-13: Central mediator of allergic asthma. Science 1998; 282:2258-2261.
53. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonaryexpression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelialfibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103:779-788.
54. Gordon JR, Galli SJ. Mast cells as a source of both preformed and immunologicallyinducible TNF-a/cachectin. Nature 1990; 346:274-276.
55. Wershil BK, Wang ZS, Gordon JR, Galli SJ. Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent—partialinhibition of the reaction with antiserum against tumor necrosis factor-a. J Clin Invest1991; 87:446-453.
56. Nagai H, Sakurai T, Abe T, Matsuo A, Musoh K, Tsunematsu M, Inagaki N. TNFaparticipates in an IgE-mediated cutaneous reaction in mast cell deficient, WBB6F1-W/Wv mice. Inflamm Res 1996; 45:136-40.
57. Sanz MJ, Hartnell A, Chisholm P, Williams C, Davies D, Weg VB, Feldmann M, Bolanowski MA, Lobb RR, Nourshargh S. Tumor necrosis factor a-induced eosinophil accumulation in rat skin is dependent on a4 integrin/vascular cell adhesion molecule-1 adhesion pathways. Blood 1997; 90:4144-4152.
58. Sanz MJ, Marinova-Mutafchieva L, Green P, Lobb RR, Feldmann M, Nourshargh S.IL-4-induced eosinophil accumulation in rat skin is dependent on endogenous TNFα and α4 integrin/VCAM-1 adhesion pathways. J Immunol 1998; 160:5637-5645.
59. Sakurai T, Inagaki N, Nagai H. The effect of anti-tumor necrosis factor (TNF)-alphamonoclonal antibody on allergic cutaneous late phase reaction in mice. Life Sci 1994;54:L291-L295.
60. Renzetti LM, Paciorek PM, Tannu SA, Rinaldi NC, Tocker JE, Wasserman MA, GaterPR. Pharmacological evidence for tumor necrosis factor as a mediator of allergicinflammation in the airways. J Pharmacol Exp Ther 1996; 278:847-853.
61. Gater PR, Renzetti LM. Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways. Agents Actions Suppl 1998; 49:67-71.
62. Broide DH, Stachnick G, Castaneda D, Nayar J, Sriramarao P. Inhibition of eosinophilicinflammation in allergen-challenged TNF receptor p55/p75- and TNF receptor p55-deficient mice. Am J Respir Cell Mol Biol 2001; 24:304-311.
63. Schleimer RP, Benenati SV, Friedman B, Bochner BS. Do cytokines play a role inleukocyte recruitment and activation in the lungs? Am Rev Respir Dis 1991; 143:1169-1174.
64. Rothenberg ME. Mechanisms of disease: Eosinophilia. N Engl J Med 1998; 338:1592-1600.
65. Galli SJ. New concepts about the mast cell. N Engl J Med 1993; 328:257-265.
66. Yuan Q, Austen KF, Friend DS, Heidtman M, Boyce JA. Human peripheral bloodeosinophils express a functional c-kit receptor for stem cell factor that stimulates verylate antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesionmolecule 1 (VCAM-1). J Exp Med 1997; 186:313-323.
67. Vliagoftis H, Metcalfe DD. Cell adhesion molecules in mast cell adhesion and migration. In: Bochner BS, ed. Adhesion Molecules in Allergic Diseases. New York: Marceldekker, Inc., 1997:151-172.
68. Kita H, Adolphson CR, Gleich GJ. Biology of eosinophils. In: E. Middleton J, ReedCE, Ellis EF, N. F. Adkinson J, Yunginger JW, Busse W, eds. Allergy Principles andPractice. 5th ed. St. Louis: Mosby, 1998:242-260.
69. Bochner BS, Schroeder J. Basophils. In: Austen KF, Frank MM, Atkinson JP, CantorH, eds. Samter’s Immunological Diseases. 6th ed. Philadelphia: Lippincott Williams &Wilkins, 2001:244-253.
70. Ebisawa M, Bochner BS, Schleimer RP. Eosinophil-endothelial interactions and transendothelial migration. In: Bochner BS, eds. Adhesion Molecules in Allergic Diseases. New York: Marcel Dekker, Inc., 1997:173-186.
71. Shahabuddin S, Ponath P, Schleimer RP. Migration of eosinophils across endothelialcell monolayers: Interactions among IL-5, endothelial-activating cytokines, and C-Cchemokines. J Immunol 2000; 164:3847-3854.
72. Yamamoto H, Sedgwick JB, Vrtis RF, Busse WW. The effect of transendothelialmigration on eosinophil function. Am J Respir Cell Mol Biol 2000; 23:379-388.
73. Lukacs NW, Kunkel SL, Strieter RM, Evanoff HL, Kunkel RG, Key ML, Taub DD.The role of stem cell factor (c-kit ligand) and inflammatory cytokines in pulmonarymast cell activation. Blood 1996; 87:2262-2268.
74. Zingoni A, Soto H, Hedrick JA, Stoppacciaro A, Storlazzi CT, Sinigaglia F, D’Ambrosio D, O’Garra A, Robinson D, Rocchi M, Santoni A, Zlotnik A, Napolitano M. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol 1998; 161:547-551.
75. D’Ambrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, Mantovani A, SinigagliaF. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activationof polarized human type 2 Th cells. J Immunol 1998; 161:5111-5115.
76. Yamamoto J, Adachi Y, Onoue Y, Adachi YS, Okabe Y, Itazawa T, Toyoda M, SekiT, Morohashi M, Matsushima K, Miyawaki T. Differential expression of the chemokinereceptors by the Th1- and Th2-type effector populations within circulating CD4+ Tcells. J Leukoc Biol 2000; 68:568-574.
77. Annunziato F, Cosmi L, Galli G, Beltrame C, Romagnani P, Manetti R, RomagnaniS, Maggi E. Assessment of chemokine receptor expression by human Th1 and Th2cells in vitro and in vivo. J Leukoc Biol 1999; 65:691-699.
78. Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, Humbert M, Kay AB. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expressionin bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1999;163:6321-6329.
79. Andrew DP, Ruffing N, Kim CH, Miao W, Heath H, Li Y, Murphy K, Campbell JJ, Butcher EC, Wu L. C-C Chemokine Receptor 4 expression defines a major subset ofcirculating nonintestinal memory T cells of both Th1 and Th2 potential. J Immunol2001; 166:103-111.
80. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, MoserB, Mackay CR. The chemokine receptors CXCR3 and CCR5 mark subsets of T cellsassociated with certain inflammatory reactions. J Clin Invest 1998; 101:746-754.
81. Matthews AN, Friend DS, Zimmerrmann N, Sarafi MN, Luster AD, Pearlman E, WertSE, Rothenberg ME. Eotaxin is required for the baseline level of tissue eosinophils.Proc Natl Acad Sci USA 1998; 95:6273-6278.
82. Mishra A, Hogan SP, Lee JJ, Foster PS, Rothenberg ME. Fundamental signals thatregulate eosinophil homing to the gastrointestinal tract. J Clin Invest 1999; 103:1719-1727.
83. Mishra A, Hogan SP, Brandt EB, Rothenberg ME. Peyer’s patch eosinophils: Identification, characterization, and regulation by mucosal allergen exposure, interleukin-5, andeotaxin. Blood 2000; 96:1538-1544.
84. Rothenberg ME, MacLean JA, Pearlman E, Luster AD, Leder P. Targeted disruptionof the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J ExpMed 1997; 185:785-790.
85. Dabbagh K, Xiao Y, Smith C, Stepick-Biek P, Kim SG, Lamm WJ, Liggitt DH, Lewis DB. Local blockade of allergic airway hyperreactivity and inflammation by thepoxvirus-derived pan-CC-chemokine inhibitor vCCI. J Immunol 2000; 165:3418-3422.
86. Chensue SW, Lukacs NW, Yang TY, Shang X, Frait KA, Kunkel SL, Kung T, Wiekow-ski MT, Hedrick JA, Cook DN, Zingoni A, Narula SK, Zlotnik A, Barrat FJ, O’GarraA, Napolitano M, Lira SA. Aberrant in vivo T helper type 2 cell response and impairedeosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med 2001;193:573-584.
87. Chvatchko Y, Hoogewerf AJ, Meyer A, Alouani S, Juillard P, Buser R, Conquet F, Proudfoot AE, Wells TN, Power CA. A key role for CC chemokine receptor 4 inlipopolysaccharide-induced endotoxic shock. J Exp Med 2000; 191:1755-1764.
88. Gerard C, Rollins BJ. Chemokines and disease. Nature Immunol 2001; 2:108-115.
89. Heath H, Qin SX, Rao P, Wu LJ, LaRosa G, Kassam N, Ponath PD, Mackay CR.Chemokine receptor usage by human eosinophils—the importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997; 99:178-184.
90. Sullivan SK, McGrath DA, Liao F, Boehme SA, Farber JM, Bacon KB. MIP-3αinduces human eosinophil migration and activation of the mitogen-activated proteinkinases (p42/p44 MAPK) J Leukoc Biol 1999; 66:674-682.
91. Bochner BS, Bickel CA, Taylor ML, MacGlashan DW, Jr, Gray PW, Raport CJ, Godiska R. Macrophage derived chemokine (MDC) induces human eosinophil chemotaxis in a CCR3- and CCR4-independent manner. J Allergy Clin Immunol 1999; 103:527-532.
92. Nagase H, Miyamasu M, Yamaguchi M, Fujisawa T, Ohta K, Yamamoto K, Morita Y, Hirai K. Expression of CXCR4 in eosinophils: Functional analyses and cytokine-mediated regulation. J Immunol 2000; 164:5935-5943.
93. Jinquan T, Jacobi HH, Jing C, Reimert CM, Quan S, Dissing S, Poulsen LK, Skov PS. Chemokine stromal cell-derived factor 1a activates basophils by means of CXCR4.J Allergy Clin Immunol 2000; 106:313-320.
94. Schleimer R, Bickel C, White J, Lim L, Bochner B, MacGlashan D, Jr. Chemokineresponses in purified human basophils (abstr). J Allergy Clin Immunol 2002; 109;574.
95. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature2000; 406:998-1001.
96. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy. J Allergy Clin Immunol 1996; 98:1-13.
97. Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, Sugimoto Y, Kobayashi T, Ushikubi F, Aze Y, Eguchi N, Urade Y, Yoshida N, Kimura K, Mizoguchi A, Honda Y, Nagai H, Narumiya S. Prostaglandin D2 as a mediator ofallergic asthma. Science 2000; 287:2013-2017.
98. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K. Prostaglandin D2 selectively induceschemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193:255-261.
99. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12:336-341.
100. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science1999; 286:2098-2102.
101. Briskin M. Pathways of cell recruitment to mucosal surfaces. In: Bochner BS, eds.Adhesion Molecules in Allergic Diseases. New York: Marcel Dekker, 1997: 105-128.
102. Wurbel MA, Philippe JM, Nguyen C, Victorero G, Freeman T, Wooding P, MiazekA, Mattei MG, Malissen M, Jordan BR, Malissen B, Carrier A, Naquet P. The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double-and single-positive thymocytes expressing the TECK receptor CCR9. Eur J Immunol2000; 30:262-271.
103. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, VierraMA, Goodman SB, Genovese MC, Wardlaw AJ, Greenberg HB, Parker CM, ButcherEC, Andrew DP, Agace WW. Lymphocyte CC. chemokine receptor 9 and epithelialthymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000; 192:761-768.
104. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, Andrew DP, WarnkeR, Ruffing N, Kassam N, Wu L, Butcher EC. The chemokine receptor CCR4 in vascularrecognition by cutaneous but not intestinal memory T cells. Nature 1999; 400:776-780.
105. Morales J, Homey B, Vicari AP, Hudak S, Oldham E, Hedrick J, Orozco R, CopelandNG, Jenkins NA, McEvoy LM, Zlotnik A, CTACK, a skin-associated chemokine thatpreferentially attracts skin-homing memory T cells. Proc Natl Acad Sci USA 1999;96:14470-14475.
106. Homey B, Wang W, Soto H, Buchanan ME, Wiesenborn A, Catron D, Muller A, McClanahan TK, Dieu-Nosjean MC, Orozco R, Ruzicka T, Lehmann P, Oldham E, Zlotnik A. Cutting edge: The orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC).J Immunol 2000; 164:3465-3470.
107. Fitzhugh DJ, Naik S, Caughman SW, Hwang ST. Cutting edge: C-C chemokine receptor 6 is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells under physiologic flow conditions In vitro. J Immunol 2000;165:6677-6681.
108. de Fougerolles AR, Sprague AG, Nickerson-Nutter CL, Chi-Rosso G, Rennert PD, Gardner H, Gotwals PJ, Lobb RR, Koteliansky VE. Regulation of inflammation bycollagen-binding integrins a1p1 and a2p1 in models of hypersensitivity and arthritis.J Clin Invest 2000; 105:721-729.
109. Ying S, Kay A. Chemokines in allergic asthma. In: Rothenberg ME, ed. Chemokinesin Allergic Disease. New York: Marcel Dekker, 2000:383-402.
110. Beck LA, Stellato C, Beall LD, Schall TJ, Leopold D, Bickel CA, Baroody F, Bochner BS, Schleimer RP. Detection of the chemokine RANTES and endothelial adhesionmolecules in nasal polyps. J Allergy Clin Immunol 1996; 98:766-780.
111. Stellato C, Beck LA, Gorgone GA, Proud D, Schall TJ, Ono SJ, Lichtenstein LM, Schleimer RP. Expression of the chemokine RANTES by a human bronchial epithelialcell line: Modulation by cytokines and glucocorticoids. J Immunol 1995; 155:410-418.
112. Stellato C, Collins P, Li H, White J, Ponath PD, Newman W, Soler D, Bickel C, LiuM, Bochner BS, Williams T, Schleimer RP. Production of the novel C-C-chemokineMCP-4 by airway cells and comparison of its biological activity to other C-C chemokines. J Clin Invest 1997; 99:926-936.
113. Lilly CM, Nakamura H, Kesselman H, NaglerAnderson C, Asano K, Garcia-ZepedaEA, Rothenberg ME, Drazen JM, Luster AD. Expression of eotaxin by human lungepithelial cells—induction by cytokines and inhibition by glucocorticoids. J Clin Invest1997; 99:1767-1773.
114. Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, Yamaguchi M, Fujisawa T, Pawankar R, Sano Y, Ohta K, Ishii A, Morita Y, Yamamoto K, Matsushima K, Yoshie O, Hirai K. Inducible expression of a Th2-type CC chemokine thymus- andactivation-regulated chemokine by human bronchial epithelial cells. J Immunol 2000;165:2205-2213.
115. Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressedby activated human bronchial epithelial cells. J Immunol 1999; 162:3549-3558.
116. Matsukura S, Stellato C, Georas SN, Casolaro V, Plitt JR, Miura K, Kurosawa S, Schindler U, Schleimer RP. Interleukin-13 upregulates eotaxin expression in airwayepithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol 2001;24:755-761.
117. Matsukura S, Stellato C, Plitt JR, Bickel C, Miura K, Georas SN, Casolaro V, SchleimerRP. Activation of eotaxin gene transcription by NF-kappa B and STAT6 in humanairway epithelial cells. J Immunol 1999; 163:6876-6883.
118. Stellato C, Matsukura S, Fal A, White J, Beck LA, Proud D, Schleimer RP. Differentialregulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J Immunol 1999; 163:5624-5632.
119. Cockcroft DW, Hargreave FE. Airway hyperresponsiveness Am Rev Respir Dis 1990;142:497-500.
120. Liu MC, Bleecker ER, Lichtenstein LM, Kagey-Sobotka A, Niv Y, McLemore TL, Permutt S, Proud D, Hubbard WC. Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting substances in the airways of mild asthmaticsubjects Am Rev Respir Dis 1990; 142:126-132.
121. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokinesin symptomatic asthma airways. J Allergy Clin Immunol 1992; 89:958-967.
122. Ghaffar O, Christodoulopoulos P, Hamid Q. Cellular sources of chemokines in allergicdiseases. In: Rothenberg ME, eds. Chemokines in Allergic Disease. New York: Marceldekker, 2000:403-424.
123. Peters SP, Zangrilli JG, Fish JE. Late phase allergic reactions. In: Middleton E, C.Reed, F. Ellis, Adkinson NF, J. Yunginger, W. Busse, eds. Allergy Principles andPractice. 5th ed. St. Louis: Mosby, 1998:342-355.
124. Calhoun WJ, Jarjour NN, Gleich GJ, Stevens CA, Busse WW. Increased airway inflammation with segmental versus aerosol antigen challenge. Am Rev Respir Dis 1993;147:1465-1471.
125. Peebles RS, Jr, Wagner EM, Liu MC, Proud D, Hamilton RG, Togias A. Allergen-induced changes in airway responsiveness are not related to indices of airway edema.J Allergy Clin Immunol 2001; 107:805-811.
126. Cockcroft DW. Airway responses to inhaled allergens. Can Respir J 1998; 5(suppl A):7A-14A.
127. Pabst R, Gehrke I. Is the bronchus-associated lymphoid tissue (BALT) an integralstructure of the lung in normal mammals, including humans? Am J Respir Cell MolBiol 1990; 3:131-135.
128. Berman J. Lymphocytes in the lung: Should we continue to exalt only BALT? Am JRespir Cell Mol Biol 1990; 3:101-102.
129. Richmond I, Pritchard GE, Ashcroft T, Avery A, Corris PA, Walters EH. Bronchusassociated lymphoid tissue (BALT) in human lung: Its distribution in smokers andnon-smokers. Thorax 1993; 48:1130-1134.
130. Bentley AM, Durham SR, Robinson DS, Menz G, Storz C, Cromwell O, Kay AB, Wardlaw AJ. Expression of endothelial and leukocyte adhesion molecules intercellularadhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1 in the bronchialmucosa in steady-state and allergen-induced asthma. J Allergy Clin Immunol 1993;92:857-868.
131. Georas SN, Liu MC, Newman W, Beall WD, Stealey BA, Bochner BS. Altered adhesion molecule expression and endothelial activation accompany the recruitment ofhuman granulocytes to the lung following segmental antigen challenge. Am J RespirCell Mol Biol 1992; 7:261-269.
132. Takahashi N, Liu MC, Proud D, Yu XY, Hasegawa S, Spannhake EW. Soluble intracellular adhesion molecule 1 in bronchoalveolar lavage fluid of allergic subjects followingsegmental antigen challenge. Am J Respir Crit Care Med 1994; 150:704-709.
133. Zangrilli JG, Shaver JR, Cirelli RA, Cho SK, Garlis CG, Falcone A, Cuss FM, Fish JE, Peters SP. sVCAM-1 levels after segmental challenge correlate with eosinophilinflux, IL-4 and IL-5 production, and the late phase response. Am J Respir Crit CareMed 1995; 151:1346-1353.
134. Liu MC, Proud D, Lichtenstein LM, Hubbard WC, Bochner BS, Stealey BA, BreslinL, Xiao H, Freidhoff LR, Schroeder JT, Schleimer RP. Effects of prednisone on thecellular responses and release of cytokines and mediators after segmental allergenchallenge of asthmatic subjects. J Allergy Clin Immunol 2001; 108:29-38.
135. Montefort S, Roche WR, Howarth PH, Djukanovic R, Gratziou C, Carroll M, SmithL, Britten KM, Haskard D, Lee TH, Holgate ST. Intercellular adhesion molecule-1(ICAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1) expression inthe bronchial mucosa of normal and asthmatic subjects. Eur Respir J 1992; 5:815-823.
136. Gosset P, Tillie-Leblond I, Janin A, Marquette CH, Copin MC, Wallaert B, TonnelAB. Increased expression of ELAM-1, ICAM-1, and VCAM-1 on bronchial biopsiesfrom allergic asthmatic patients. Ann NY Acad Sci 1994; 725:163-172.
137. Ohkawara Y, Yamauchi K, Maruyama N, Hoshi H, Ohno I, Honma M, Tanno Y, Tamura G, Shirato K, Ohtani H. In situ expression of the cell adhesion molecules inbronchial tissues from asthmatics with air flow limitation: In vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration. Am J Respir Cell Mol Biol1995; 12:4-12.
138. Fukuda T, Fukushima Y, Numao T, Ando N, Arima M, Nakajima H, Sagara H, AdachiT, Motojima S, Makino S. Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Am J RespirCell Mol Biol 1996; 14:84-94.
139. Hakansson L, Bjornsson E, Janson C, Schmekel B. Increased adhesion to vascular celladhesion molecule-1 and intercellular adhesion molecule-1 of eosinophils from patientswith asthma. J Allergy Clin Immunol 1995; 96:941-950.
140. Montefort S, Holgate ST. Expression of cell adhesion molecules in asthma. In: Bochnerbs, eds. Adhesion Molecules in Allergic Diseases. New York: Marcel Dekker, Inc.,1997:315-338.
141. Koizumi A, Hashimoto S, Kobayashi T, Imai K, Yachi A, Horie T. Elevation of serumsoluble vascular cell adhesion molecule-1 (sVCAM-1) levels in bronchial asthma. ClinExp Immunol 1995; 101:468-473.
142. Erle DJ, Brown T, Christian D, Aris R. Lung epithelial lining fluid T cell subsetsdefined by distinct patterns of β7 and β1 integrin expression. Am J Respir Cell MolBiol 1994; 10:237-244.
143. Erle DJ, Pabst R. Intraepithelial lymphocytes in the lung: A neglected lymphocytepopulation. Am J Respir Cell Mol Biol 2000; 22:398-400.
144. Campbell JJ, Brightling CE, Symon FA, Qin S, Murphy KE, Hodge M, Andrew DP, Wu L, Butcher EC, Wardlaw AJ. Expression of chemokine receptors by lung T cellsfrom normal and asthmatic subjects. J Immunol 2001; 166:2842-2848.
145. Leung DYM, Picker LJ. Adhesion pathways controlling recruitment responses of lymphocytes during allergic inflammatory reactions in vivo. In: Bochner BS, eds. AdhesionMolecules in Allergic Diseases. New York: Marcel Dekker, 1997:297-314.
146. Fournier M, Lebargy F, Le Roy Ladurie F, Lenormand E, Pariente R. IntraepithelialT-lymphocyte subsets in the airways of normal subjects and of patients with chronicbronchitis. Am Rev Respir Dis 1989; 140:737-742.
147. Goto E, Kohrogi H, Hirata N, Tsumori K, Hirosako S, Hamamoto J, Fujii K, Kawano O, Ando M. Human bronchial intraepithelial T lymphocytes as a distinct T-cell subset: Their long-term survival in SCID-Hu chimeras. Am J Respir Cell Mol Biol 2000; 22: 405-411.
148. Schon MP, Arya A, Murphy EA, Adams CM, Strauch UG, Agace WW, Marsal J, Donohue JP, Her H, Beier DR, Olson S, Lefrancois L, Brenner MB, Grusby MJ, Parker CM. Mucosal T lymphocyte numbers are selectively reduced in integrin alphaE (CD103)-deficient mice. J Immunol 1999; 162:6641-6649.
149. Hansel TT, Walker C. The migration of eosinophils into the sputum of asthmatics: Therole of adhesion molecules. Clin Exp Allergy 1992; 22:345-356.
150. Kroegel C, Liu MC, Hubbard WM, Lichtenstein LM, Bochner BS. Blood and bron-choalveolar eosinophils in allergic subjects following segmental antigen challenge:surface phenotype, density heterogeneity, and prostanoid production. J Allergy ClinImmunol 1994; 93:725-734.
151. Matsumoto K, Appiah-Pippim J, Schleimer RP, Bickel CA, Beck LA, Bochner BS.CD44 and CD69 represent different types of cell surface activation markers for humaneosinophils. Am J Respir Cell Mol Biol 1998; 18:860-866.
152. Bochner BS. Systemic activation of basophils and eosinophils: Markers and consequences. J Allergy Clin Immunol 2000; 106:S292-S302.
153. Wilson SJ, Wallin A, Della-Cioppa G, Sandstrom T, Holgate ST. Effects of budesonideand formoterol on NFkB, adhesion molecules, and cytokines in asthma. Am J RespirCrit Care Med 2001; 164:1047-1052.
154. Bochner BS. Cellular adhesion and its antagonism. J Allergy Clin Immunol 1997; 100:581-585.
155. Schleimer RP, Bochner BS. The role of adhesion molecules in allergic inflammationand their suitability as targets of antiallergic therapy. Clin Exp Allergy 1998; 28:15-23.
156. Bochner BS. Adhesion molecule antagonism: An overview. In: Hansel TT, Barnes P, eds. New Drugs for Asthma, Allergy and COPD. Progress in Respiratory Research.Basel: Karger, 2001:298-301.
157. Kavanaugh A. Overview of cell adhesion molecules and their antagonism. In: Bochnerbs, ed. Cell Adhesion Molecules in Allergic Disease. New York: Marcel Dekker,1997:1-24.
158. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, Hughes RA, Palace J, Sharrack B, Swingler R, Young C, Moseley IF, MacManus DG, Donoghue S, Miller DH. The effect of anti-a4 integrin antibody on brain lesion activity in MS.Neurology 1999; 53:466-472.
159. Miller D, Khan O, Sheremata W, Blumhardt L, Rice G, O’Connor P. Results of adouble-blind, randomized, placebo-controlled, phase II trial of Antegren (natalizumab)in subjects with relapsing multiple sclerosis. Multiple Sclerosis 2001; 7:s16.
160. Lobb RR. Adhesion molecule antagonists in animal models of asthma. In: Bochnerbs, ed. Adhesion Molecules in Allergic Diseases. New York: Marcel Dekker, Inc.,1997:396-406.
161. Wegner CD, Gundel RH, Letts LG. Expression and probable roles of cell adhesionmolecules in lung inflammation. Chest 1992; 101:34S-39S.
162. Berens KL, Vanderslice P, Dupre B, Dixon RA. F. Selectin antagonists. In: Hanseltt, Barnes P, eds. New Drugs for Asthma, Allergy and COPD. Progress in RespiratoryResearch. Basel: Karger, 2001:306-309.
163. Adams SP, Lobb RR. Small-molecule VLA-4 antagonists. In: Hansel TT, Barnes P, eds. New Drugs for Asthma, Allergy and COPD. Progress in Respiratory Research.Basel: Karger, 2001:302-305.
164. Richards IM, Khare Slatter V. ICAM-1 and VCAM-1 antagonists. In: Hansel TT, Barnes P, eds. New Drugs for Asthma, Allergy and COPD. Progress in RespiratoryResearch. Basel: Karger, 2001:310-313.
165. Peebles RS, Bochner BS, Schleimer RP. Pharmacologic regulation of adhesion molecule function and expression. In: Ruffolo J, Hollinger MA, eds. Inflammation: Mediators and Pathways. Boca Raton, FL.: Crc Press, 1995:29-97.
166. Hamid QA, Minshall EM. Molecular pathology of allergic disease: I: Lower airwaydisease. J Allergy Clin Immunol 2000; 105:20-36.
167. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC, Jr. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production inperipheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992; 146:109-115.
168. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, CorriganC, Durham SR, Kay AB. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
169. Ying S, Robinson DS, Varney V, Meng Q, Tsicopoulos A, Moqbel R, Durham SR, Kay AB, Hamid Q. TNFa mRNA expression in allergic inflammation. Clin Exp Allergy 1991; 21:745-750.
170. Bradding P, Mediwake R, Feather IH, Madden J, Church MK, Holgate ST, Howarth PH. TNFa is localized to nasal mucosal mast cells and is released in acute allergic rhinitis Clin Exp Allergy 1995; 25:406-415.
171. Hamilos DL, Leung DYM, Wood R, Bean DK, Song YL, Schotman E, Hamid Q.Eosinophil infiltration in nonallergic chronic hyperplastic sinusitis with nasal polyposisis associated with endothelial VCAM-1 upregulation and expression of TNF-α. Am JRespir Cell Mol Biol 1996; 15:443-450.
172. Weinberger MS, Davidson TM, Broide DH. Differential expression of vascular celladhesion molecule mRNA and protein in nasal mucosa in response to IL-1 or tumornecrosis factor. J Allergy Clin Immunol 1996; 97:662-671.
173. Broide DH, Firestein GS. Endobronchial allergen challenge in asthma. Demonstrationof cellular source of granulocyte macrophage colony-stimulating factor by in situ hybridization. J Clin Invest 1991; 88:1048-1053.
174. Massey W, Friedman B, Kato M, Cooper P, Kagey-Sobotka A, Lichtentein LM, Schleimer RP. Appearance of IL-3 and GM-CSF activity at allergen-challenged cutaneous late-phase reaction sites. J Immunol 1993; 150:1084-1092.
175. Ohnishi T, Kita H, Weiler D, Sur S, Sedgwick JB, Calhoun WJ, Busse WW, Abrams JS, Gleich GJ. IL-5 is the predominant eosinophil-active cytokine in the antigen-inducedpulmonary late-phase reaction. Am Rev Respir Dis 1993; 147:901-907.
176. Ebisawa M, Liu MC, Yamada T, Kato M, Lichtenstein LM, Bochner BS, Schleimer RP. Eosinophil transendothelial migration induced by cytokines II. The potentiationof eosinophil transendothelial migration by eosinophil-active cytokines. J Immunol1994; 152:4590-4597.
177. Gauvreau GM, O’Byrne PM, Moqbel R, Velazquez J, Watson RM, Howie KJ, Denburg JA. Enhanced expression of GM-CSF in differentiating eosinophils of atopic and atopicasthmatic subjects. Am J Respir Cell Molec Biol 1998; 19:55-62.
178. Robinson D, Hamid Q, Ying S, Bentley A, Assoufi B, Durham S, Kay AB. Prednisolonetreatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-y cytokine gene expression. Am Rev RespirDis 1993; 148:401-406.
179. Sousa AR, Poston RN, Lane SJ, Nakhosteen JA, Lee TH. Detection of GM-CSF inasthmatic bronchial epithelium and decrease by inhaled corticosteroids. Am Rev RespirDis 1993; 147:1557-1561.
180. Davies RJ, Wang JH, Trigg CJ, Devalia JL. Expression of GM-CSF, IL-8 and RANTESbronchial epithelium of mild asthmatics is down regulated by inhaled beclomethasonedipropionate. Int Arch Allergy Immunol 1994; 107:428-429.
181. Shi HZ, Deng JM, Xu H, Nong ZX, Xiao CQ, Liu ZM, Qin SM, Jiang HX, Liu GN, Chen YQ. Effect of inhaled interleukin-4 on airway hyperreactivity in asthmatics. AmJ Respir Crit Care Med 1998; 157:1818-1821.
182. Shi HZ, Xiao CQ, Zhong D, Qin SM, Liu Y, Liang GR, Xu H, Chen YQ, Long XM, Xie ZF. Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia inasthmatics. Am J Respir Crit Care Med 1998; 157:204-209.
183. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L.Interleukin-4 receptor in moderate atopic asthma—a phase I/II randomized, placebocontrolled trial. Am J Respir Crit Care Med 1999; 160:1816-1823.
184. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM.Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J AllergyClin Immunol 2001; 107:963-970.
185. Groopman JE, Mitsuyasu RT, DeLeo MJ, Oette DH, Golde DW. Effect of recombinanthuman granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987; 317:593-598.
186. Stirling RG, van Rensen EL, Barnes PJ, Chung KF. Interleukin-5 induces CD34(+)eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am JRespir Crit Care Med 2001; 164:1403-1409.
187. van Rensen EL, Stirling RG, Scheerens J, Staples K, Sterk PJ, Barnes PJ, Chung KF.Evidence for systemic rather than pulmonary effects of interleukin-5 administrationin asthma. Thorax 2001; 56:935-940.
188. Leckie MJ, Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ.Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000; 356:2144-2148.
189. O’Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma J Allergy Clin Immunol 2001; 108:503-508.
190. Barnes PJ. Therapeutic strategies for allergic diseases. Nature 1999; 402:B31-38.
191. Barnes P. New directions in allergic diseases: Mechanism-based anti-inflammatorytherapies. J Allergy Clin Immunol 2000; 106:5-16.
192. Nickel R, Beck LA, Stellato C, Schleimer RP. Chemokines and allergic disease. JAllergy Clin Immunol 1999; 104:723-742.
193. Berkman N, Ohnona S, Chung FK, Breuer R. Eotaxin-3 but not eotaxin gene expressionis upregulated in asthmatics 24 hours after allergen challenge. Am J Respir Cell MolBiol 2001; 24:682-687.
194. Pan J, Kunkel EJ, Gosslar U, Lazarus N, Langdon P, Broadwell K, Vierra MA, Genovese MC, Butcher EC, Soler D. A novel chemokine ligand for CCR10 and CCR3expressed by epithelial cells in mucosal tissues. J Immunol 2000; 165:2943-2949.
195. Kuna P, Alam R, Ruta U, Gorski P. RANTES induces nasal mucosal inflammationrich in eosinophils, basophils, and lymphocytes in vivo Am J Respir Crit Care Med1998; 157:873-879.
196. Hanazawa T, Antuni JD, Kharitonov SA, Barnes PJ. Intranasal administration of eo-taxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis. JAllergy Clin Immunol 2000; 105:58-64.
197. Beck LA, Dalke S, Leiferman KM, Bickel CA, Hamilton R, Rosen H, Bochner BS, Schleimer RP. Cutaneous injection of RANTES causes eosinophil recruitment: Comparison of nonallergic and allergic human subjects. J Immunol 1997; 159:2962-2972.
198. Teran LM. CCL chemokines and asthma. Immunol Today 2000; 21:235 -242.
199. Gonzalo J, Lloyd C, Peled A, Delaney T, Coyle A, Gutierrez-Ramos J. Critical involvement of the chemotactic axis CXCR4/stromal cell-derived factor-1a in the inflammatory component of allergic airway disease. J Immunol 2000; 165:499-508.
200. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptorCCR3 by human T helper 2 cells. Science 1997; 277:2005-2007.
201. Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, Mackay CR, Daugherty BL, Springer MS, Durham SR, Williams TJ, Kay AB. Enhanced expressionof eotaxin and CCR3 mRNA and protein in atopic asthma. Eur J Immunol 1997; 27:3507-3516.
202. Arima M, Plitt J, Stellato C, Bickel C, Motojima S, Makino S, Fukuda T, SchleimerRP. Expression of interleukin-16 by human epithelial cells. Am J Respir Cell Mol Biol1999; 21:684-692.
203. Krug N, Cruikshank WW, Tschernig T, Erpenbeck VJ, Balke K, Hohlfeld JM, Center DM, Fabel H. Interleukin 16 and T-cell chemoattractant activity in bronchoalveolarlavage 24 hours after allergen challenge in asthma. Am J Respir Crit Care Med 2000;162:105-111.
204. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2- mediated responses. Immunol Today 1998; 19:568-574.
205. Panina-Bordignon P, Papi A, Mariani M, Di Lucia P, Casoni G, Bellettato C, BuonsantiC, Miotto D, Mapp C, Villa A, Arrigoni G, Fabbri LM, Sinigaglia F. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopicasthmatics. J Clin Invest 2001; 107:1357-1364.